Aclaris Therapeutics ACRS Royalty — Contract With Customer Liability Current
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
The Company evaluated the arrangement and concluded that the proceeds from the sale of future royalties should be recorded as deferred income on the condensed consolidated balance sheet, as the criteria for debt classification were not met in accordance with ASC Topic 470. In particular, the Company does not have significant continuing involvement in the generation of the cash flows due to OMERS and there are no guaranteed rates of return to OMERS. The Company recognized $1.0 million of non-cash royalty income for each of the three months ended June 30, 2026 and 2025, and $1.8 million for each of the six months ended June 30, 2026 and 2025. As of June 30, 2026, the current and non-current portions of the remaining deferred income recognized under the units-of-revenue method were $4.0 million and $14.3 million, respectively. As of December 31, 2025, the current and non-current portions of the remaining deferred income recognized under the units-of-revenue method were $3.9 million and $16.2 million, respectively.
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's royalty — contract with customer liability current?
- Aclaris Therapeutics (ACRS) reported royalty — contract with customer liability current of $4M in Q2 2026.
- How has Aclaris Therapeutics's royalty — contract with customer liability current changed year-over-year?
- Aclaris Therapeutics's royalty — contract with customer liability current increased by 2.6% year-over-year, from $3.9M to $4M.
- What does royalty — contract with customer liability current mean?
- This represents the portion of deferred revenue or performance obligations related to royalty agreements that the company expects to satisfy within the next twelve months. It reflects payments received or amounts billed in advance of fulfilling specific contractual obligations tied to royalty-generating assets. Monitoring this balance helps investors understand the short-term revenue recognition pipeline from licensing and royalty arrangements.
Ask your AI about Aclaris Therapeutics's royalty — contract with customer liability current.
Connect your AI assistant and compare it to peers, right in your chat.
